These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15771919)

  • 41. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
    Kitamoto S; Nakano K; Hirouchi Y; Kohjimoto Y; Kitajima S; Usui M; Inoue S; Egashira K
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1522-8. PubMed ID: 15178560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cholesterol and vascular disease. Study of pravastatin ].
    Bellandi F; Cantini F; Pedone T; Palchetti R
    Clin Ter; 1993 May; 142(5):439-43. PubMed ID: 8339527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan.
    Matsushita Y; Sugihara M; Kaburagi J; Ozawa M; Iwashita M; Yoshida S; Saito H; Hattori Y
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):196-202. PubMed ID: 19856484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary prevention of coronary artery disease.
    Domanski MJ
    N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
    [No Abstract]   [Full Text] [Related]  

  • 46. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
    Scheen AJ
    Rev Med Liege; 1999 Jan; 54(1):2-3. PubMed ID: 10081301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.
    Krecki R; Drozdz J; Szcześniak P; Orszulak-Michalak D; Krzemińska-Pakuła M
    Kardiol Pol; 2008 Nov; 66(11):1173-80; discussion 1181-2. PubMed ID: 19105094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Med; 2005 Dec; 118 Suppl 12A():22-7. PubMed ID: 16356804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. National Cholesterol Education Panel III guidelines performance role in preventing myocardial infarction in a large cohort without a history of coronary artery disease: Korea Acute Myocardial Infarction Registry study.
    Yoon YE; Rivera JJ; Kwon DA; Chae IH; Jeong MH; Rha SW; Blumenthal RS; Nasir K; Chang HJ;
    Prev Cardiol; 2009; 12(2):109-13. PubMed ID: 19476585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
    Brophy JM; Brassard P; Bourgault C
    Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic syndrome abating the beneficial effect of pravastatin treatment on adhesion of endothelium by monocytes in subjects with hypercholesterolemia.
    Lee IT; Lee WJ; Ou HC; Huang CN; Sheu WH
    Metabolism; 2009 Mar; 58(3):416-20. PubMed ID: 19217460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achieving cholesterol target in a managed care organization (ACTION) trial.
    Straka RJ; Taheri R; Cooper SL; Smith JC
    Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of pravastatin and diet in the treatment of hypercholesterolemia].
    Palazzuoli V; Mondillo S; Faglia S; D'Aprile N; Mangiacotti L
    Clin Ter; 1995 Oct; 146(10):587-93. PubMed ID: 8585875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, multicentre, open-label, parallel-group trial to compare the efficacy and safety profile of daming capsule in patients with hypercholesterolemia.
    Jing A; Li-Mei Z; Yan-Jie L; Ben-Zhi C; Yong Z; Bao-Feng Y
    Phytother Res; 2009 Jul; 23(7):1039-42. PubMed ID: 19145637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
    Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
    Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
    Naslafkih A; Sestier F
    J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.